Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Racial differences in CYP3A5 polymorphisms don't affect tamoxifen metabolism
March 31st, 2005
African American and white women exhibit different prevalence of CYP3A5 polymorphisms, but these don't appear to affect tamoxifen metabolism in postmenopausal women of either race with breast cancer. University of Maryland researchers wrote, "Tamoxifen (TAM) is widely used for treatment and prevention of breast cancer. TAM is metabolized by cytochrome P450 (CYP450) enzymes, including CYP3A5. Although two genetic polymorphisms in CYP3A5 are known (CYP3A5*3 and CYP3A5*6), the effects of these polymorphisms on TAM metabolism, TAM side effects, and tumor characteristics are unknown." A.N. Tucker and colleagues "tested the hypothesis that CYP3A5...
Source: Women's Health Weekly (2005-03-31)
|
